Edition:
United Kingdom

DBV Technologies SA (DBV.PA)

DBV.PA on Paris Stock Exchange

36.56EUR
26 Apr 2018
Change (% chg)

€-0.18 (-0.49%)
Prev Close
€36.74
Open
€36.54
Day's High
€36.80
Day's Low
€36.20
Volume
58,846
Avg. Vol
135,687
52-wk High
€86.64
52-wk Low
€32.88

Chart for

About

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to... (more)

Overall

Beta: 0.28
Market Cap(Mil.): €1,130.10
Shares Outstanding(Mil.): 29.80
Dividend: --
Yield (%): --

Financials

  DBV.PA Industry Sector
P/E (TTM): -- 29.67 32.21
EPS (TTM): -5.97 -- --
ROI: -73.78 13.44 13.05
ROE: -79.24 15.16 14.90

BRIEF-DBV Technologies: Closing Of Underwriters' Option To Purchase Additional Shares In Global Offering

* REG-DBV TECHNOLOGIES ANNOUNCES CLOSING OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES IN GLOBAL OFFERING

26 Mar 2018

BRIEF-DBV Technologies Announces Pricing Of 122.5 Million Euros Global Offering Of Ordinary Shares

* ANNOUNCES PRICING OF $150.0 MILLION (EUR 122.5 MILLION) GLOBAL OFFERING OF ORDINARY SHARES

21 Mar 2018

BRIEF-DBV Technologies ‍Announces Intention To Issue And Sell Up To $150 Mln Of New Ordinary Shares​

* DBV TECHNOLOGIES ANNOUNCES THE LAUNCH OF A PROPOSED GLOBAL OFFERING OF ORDINARY SHARES, WHICH MAY BE IN THE FORM OF AMERICAN DEPOSITARY SHARES

20 Mar 2018

BRIEF-DBV Technologies FY Net Loss widens to 147.7 Million Euros

* CASH AND CASH EQUIVALENTS AS OF DEC 31, 2017 EUR 137.9 MILLION VERSUS EUR 256.5 MILLION YEAR AGO

14 Mar 2018

BRIEF-DBV Technologies Announces Result From Phase II Study of Viaskin Milk

* ANNOUNCED ON MONDAY, RESULT FROM PHASE II STUDY OF VIASKIN MILK IN MILK-ALLERGIC PATIENTS

27 Feb 2018

BRIEF-DBV Technologies Announces Results From Phase II Study Of Viaskin Milk In Milk-Allergic Patients

* DBV TECHNOLOGIES ANNOUNCES RESULTS FROM PHASE II STUDY OF VIASKIN MILK IN MILK-ALLERGIC PATIENTS

26 Feb 2018

BRIEF-DBV Technologies Cash And Cash Equivalents At Dec. 31 Down At 137.9 Million Euros

* ‍CASH AND CASH EQUIVALENTS AS OF DECEMBER 31, 2017, WERE EUR 137.9 MILLION, VERSUS EUR 256.5 MILLION YEAR AGO Source text for Eikon: Further company coverage: (Gdynia Newsroom)

20 Feb 2018

BRIEF-Reg-Dbv Technologies Provides Update On Regulatory Progress For Viaskin Peanut

* REG-DBV TECHNOLOGIES PROVIDES UPDATE ON REGULATORY PROGRESS FOR VIASKIN PEANUT

14 Feb 2018

BRIEF-DBV Technologies ‍announces positive data from Phase IIb trial and long-term study of Viaskin Peanut​

* ‍ANNOUNCES PUBLICATION OF POSITIVE DATA FROM PHASE IIB TRIAL AND LONG-TERM STUDY OF VIASKIN PEANUT​

14 Nov 2017

BRIEF-DBV Technologies reports at Sept. 30 cash position of 170.5 million euros

* CASH POSITION AT SEPT. 30, 2017 EUR 170.5 MILLION VERSUS EUR 256.5 MILLION AT DEC. 31, 2016 ‍​ Source text: http://bit.ly/2htbI61 Further company coverage: (Gdynia Newsroom)

31 Oct 2017

Earnings vs. Estimates